How India Exports Anastrozole to the World

Anastrozole has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of breast cancer in postmenopausal women. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for Anastrozole, indicating a competitive generic market. The primary regulatory pathway for Anastrozole involves the submission of an ANDA, demonstrating bioequivalence to the reference listed drug (RLD). As of December 2025, the FDA introduced updates to the Orange Book to clarify the identification of RLDs and reference standards, facilitating the ANDA submission process.

Given the substantial number of Indian exporters (158) supplying Anastrozole to the U.S., it is imperative for these entities to adhere strictly to FDA regulations. This includes compliance with Current Good Manufacturing Practices (cGMP) and ensuring that their products meet the required standards for safety, efficacy, and quality.

In the European Union, Anastrozole is authorized for the treatment of hormone receptor-positive advanced breast cancer in postmenopausal women. The European Medicines Agency (EMA) has conducted periodic safety update report single assessments (PSUSAs) for Anastrozole, with the most recent assessment completed in May 2025. (ema.europa.eu) This underscores the EMA's commitment to ongoing pharmacovigilance and the maintenance of up-to-date safety information.

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) authorized Anastrozole in November 2023 for the prevention of breast cancer in postmenopausal women at moderate or high risk. (gov.uk) This expanded indication reflects the evolving therapeutic applications of Anastrozole within the UK market.

Manufacturers exporting Anastrozole to the EU and UK must comply with the respective regulatory requirements, including obtaining marketing authorizations and adhering to Good Manufacturing Practice (GMP) standards as stipulated by the EMA and MHRA.

Anastrozole is included in the World Health Organization's (WHO) Model List of Essential Medicines, highlighting its significance in global health. The drug is also subject to international pharmacopoeial standards, including those of the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Compliance with these standards ensures the quality, safety, and efficacy of Anastrozole across different markets.

In India, Anastrozole is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, Anastrozole is not listed under the Drugs (Prices Control) Order (DPCO), and thus, its price is not subject to government-mandated ceilings. For export purposes, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national export regulations.

The primary patents for Anastrozole have expired, leading to the availability of generic versions in various markets. This has resulted in increased competition among manufacturers and exporters, particularly from India, which has become a significant supplier of generic Anastrozole globally.

In May 2025, the EMA completed a periodic safety update report single assessment (PSUSA) for Anastrozole, leading to variations in the product information to enhance safety and efficacy profiles. (ema.europa.eu)

In November 2023, the MHRA authorized Anastrozole for the prevention of breast cancer in postmenopausal women at moderate or high risk, expanding its therapeutic indications in the UK. (gov.uk)

These developments underscore the dynamic regulatory landscape surrounding Anastrozole, necessitating continuous monitoring by exporters to ensure compliance and market competitiveness.

Anastrozole's Active Pharmaceutical Ingredient (API) production is heavily reliant on Key Starting Materials (KSMs) such as 2,3,5-trimethoxybenzaldehyde, predominantly sourced from China. This dependency exposes the supply chain to significant risks, as disruptions in Chinese manufacturing—due to environmental regulations or geopolitical tensions—can directly impact API availability. For instance, environmental shutdowns in China's Jiangsu Province in 2022 affected approximately 30% of global intermediate production, leading to delays in API manufacturing timelines.

Furthermore, China's control over 70–80% of global KSM supply and 60–70% of intermediate supply underscores the strategic vulnerability in the pharmaceutical supply chain. This concentration means that any disruption in Chinese exports can have cascading effects on global API production, including that of Anastrozole.

Our proprietary trade data indicates that the top five Indian exporters account for 96.4% of Anastrozole exports, with INTAS PHARMACEUTICALS LIMITED alone contributing 84.7% ($93.8M) of the total export value. This high supplier concentration poses a significant single-source risk; any operational or regulatory issues at INTAS could severely disrupt the global supply of Anastrozole.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at reducing import dependence on critical pharmaceutical ingredients. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and Clavulanic Acid, marking a step towards enhancing domestic production capabilities.

Recent geopolitical tensions have led to the closure of the Strait of Hormuz, a critical chokepoint through which approximately 20% of global oil passes. This disruption has halted commercial shipping in the region, affecting the transportation of pharmaceuticals and other goods. Additionally, the Red Sea and the Bab al-Mandab Strait have experienced increased threats to commercial shipping, further complicating global supply chains.

While specific FDA or EMA shortage alerts for Anastrozole have not been issued as of March 2026, the ongoing conflicts and shipping disruptions pose a potential risk to its global supply. The longer these disruptions persist, the higher the likelihood of shortages and price increases for critical medications, including Anastrozole.

• Diversify Supplier Base: Encourage the development of additional manufacturing facilities for Anastrozole to reduce reliance on a single supplier.

• Enhance Domestic Production: Support initiatives like the PLI scheme to bolster domestic production of APIs and KSMs, decreasing dependency on imports.

• Strengthen Supply Chain Resilience: Develop contingency plans, including alternative shipping routes and increased inventory levels, to mitigate the impact of geopolitical disruptions.

• Monitor Regulatory Compliance: Ensure that all suppliers adhere to international quality standards to prevent regulatory issues that could disrupt supply.

• Engage in Strategic Partnerships: Collaborate with multiple international suppliers to create a more robust and flexible supply chain network.

RISK_LEVEL: HIGH